Citi raised the firm’s price target on Insulet to $310 from $283 and keeps a Buy rating on the shares as part of a 2025 outlook for the U.S. medical technology sector. The stocks that outperformed in 2024 followed the traditional med tech path, and Citi expects the same in 2025: launching differentiated products that can be leveraged to the bottom-line, with management teams providing consistent delivery, the analyst tells investors in a research note. Citi names Boston Scientific (BSX) and Insulet (PODD) its top picks for 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target raised to $317 from $234 at Morgan Stanley
- Insulet price target raised to $234 from $220 at Barclays
- Early notable gainers among liquid option names on November 8th
- Insulet price target raised to $270 from $260 at BTIG
- Insulet Reports Strong Revenue Growth and Optimistic Outlook